Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 31, 2006
Zelenkofske to lead development and implementation of pre- and post-market clinical strategy that supports Company's CRM technology and therapy portfolio
-
Oct 25, 2006
Positive results also reported for TAXUS Liberte stent direct stenting
-
Oct 25, 2006
Results were announced at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington, D.C.
-
Oct 23, 2006
Results also show statistically significant late stent thrombosis rate for Cypher® stent vs. bare-metal stent
-
Oct 23, 2006
Two-year results continue to evaluate long-term safety and efficacy
-
Oct 23, 2006
Multi-center registry to enroll 10,000 patients over two years
-
Oct 22, 2006
Study of 1,558 patients was designed to retrospectively compare one-year clinical outcomes in real-world practice
-
Oct 18, 2006
"In Q3 we were able to achieve results near the high end of our previously announced preliminary sales and earnings ranges," said Jim Tobin, President and CEO
-
Oct 18, 2006
Results to include new data on next-generation TAXUS® Liberte™ Stent System
-
Oct 16, 2006
MAPS trial demonstrates Company's commitment to understanding the efficacy and durability of endovascular therapies for the treatment of brain aneurysms